Groundbreaking Results from STEP Young Trial Show Wegovy® Effectively Reduces BMI in Children Ages 6 to 12
Wegovy® Shows Exciting Results in Childhood Obesity Treatment
The health community is abuzz after Nov Nordisk's recent announcement detailing the results from the STEP Young trial, a pivotal phase 3 study exploring the safety and efficacy of semaglutide, marketed as Wegovy®. This innovative drug aims to treat childhood obesity, a growing epidemic that affects millions globally. The findings, which made headlines during ObesityWeek® 2026 and were simultaneously published in The New England Journal of Medicine, reveal that Wegovy® has led to remarkable reductions in body mass index (BMI) for children aged 6 to under 12.
In this landmark trial involving 167 participants, nearly 80% of the children treated with Wegovy® experienced a BMI reduction of 10% or more. In stark contrast, 0% of those on the placebo showed any significant change. Notably, the trial demonstrated a mean percentage change in BMI of -17.4% in the semaglutide group versus +2.2% in the placebo group after 68 weeks. The implications of these results are profound, especially given that childhood obesity is associated with numerous health risks, including type 2 diabetes and hypertension.
Considerations and Implications
Dr. Ania M. Jastreboff of Yale University, a prominent figure in the trial, highlighted that severe obesity can severely compromise a child's physical and emotional well-being. As such, the successful reduction in BMI with semaglutide might not merely address weight issues but also prevent lasting health problems that could emerge later in life. This study shines a spotlight on obesity as a serious chronic disease while advocating for evidence-based treatment approaches that acknowledge its multifactorial nature.
Participants in the trial followed a structured program that combined Wegovy® administration with lifestyle modifications such as dietary changes and increased physical activity. This integrated approach is crucial for creating sustainable health improvements and is representative of a significant shift in treating obesity as a chronic condition rather than a temporary setback.
Safety and Tolerability of Semaglutide
The trial also assessed the safety and tolerability of semaglutide, which aligned with previously documented data from both adult and pediatric studies conducted by Novo Nordisk. No unexpected safety concerns were raised, with common side effects including nausea and gastrointestinal symptoms, which are typical with weight management medications. The drug carries a boxed warning regarding potential thyroid tumors and is not approved for individuals with certain pre-existing conditions.
A Societal Perspective on Childhood Obesity
Obesity Action Coalition's President, Joe Nadglowski, emphasized the necessity of compassionate care that combats weight bias and stigma. With the STEP Young results, the potential for improved management of pediatric obesity becomes increasingly evident. Children's quality of life can significantly increase through accessible, effective interventions, and this trial represents an essential step toward understanding viable treatments for a complex, often misunderstood health condition.
Future Directions for Obesity Treatment
The STEP trial marks a significant milestone in pediatric obesity research and encourages healthcare systems worldwide to prioritize focused interventions that address the multiple dimensions of obesity. While Wegovy® is not yet approved for use in children in the US, the promising data from this trial may catalyze advancements in regulatory approvals and broaden understanding of available treatments for childhood obesity.
As a society, we face the challenge of tackling the childhood obesity crisis head-on. The STEP Young trial not only illuminates a pathway forward for better treatment options but also highlights the importance of supporting families and children affected by obesity through comprehensive and thoughtful healthcare practices. The results from this trial could pave the way for significant changes in how childhood obesity is treated, offering hope to millions seeking healthier futures.